Age‑dependent mitochondrial MOTS‑c accumulation reflects a vesicular sequestration mechanism that uncouples intracellular signaling from circulating levels

Stefan Bauer (MD/PhD)· Mar 26, 2026

Mechanism: With age, MOTS-c peptides are sequestered into extracellular vesicles (EVs) and exported, reducing free cytosolic MOTS-c and inactivating the beneficial AMPK pathway. Readout: Readout: Inhibiting EV release with GW4869 increases cytosolic MOTS-c, restores AMPK signaling, and improves muscle insulin sensitivity and strength.

Hypothesis

The age‑associated rise in skeletal muscle MOTS‑c does not indicate enhanced retrograde signaling but rather a compensatory sequestration of the peptide into extracellular vesicles (EVs) that limits its bioavailability in circulation. Consequently, plasma MOTS‑c fails to reflect mitochondrial stress or longevity‑related activity, explaining the discordant tissue‑vs‑blood patterns observed in humans.

Mechanistic Rationale

MOTS‑c synthesis and mitochondrial retention – Under rising mitochondrial ROS with age, MOTS‑c translation increases as part of the mitochondrial stress response (see ’s discussion of compensatory accumulation).
Vesicular loading – Cytosolic MOTS‑c is recognized by the ESCRT‑dependent sorting machinery via a C‑terminal basic motif (predicted by ModeReduction) and packaged into small EVs that are exported to the interstitial space.
Plasma dilution and clearance – EV‑associated MOTS‑c is rapidly taken up by macrophages or degraded in the lymph, resulting in low and variable plasma concentrations that do not correlate with tissue levels.
Signaling consequence – Sequestration reduces free cytosolic MOTS‑c, attenuating its putative activation of AMPK‑SIRT1‑PGC‑1α axis; the cell instead relies on alternative stress pathways (e.g., ATF4‑CHOP) to maintain homeostasis.

Testable Predictions

Prediction 1: In aged mouse skeletal muscle, the proportion of MOTS‑c associated with EVs (isolated by ultracentrifugation or size‑exclusion chromatography) will be significantly higher than in young muscle, while total muscle MOTS‑c rises.
Prediction 2: Plasma MOTS‑c levels will show no correlation with EV‑associated muscle MOTS‑c across individuals, but EV‑associated muscle MOTS‑c will inversely correlate with phospho‑AMPK activity in the same tissue.
Prediction 3: Genetic or pharmacological inhibition of EV release (e.g., GW4869 to block neutral sphingomyelinase) in aged mice will increase cytosolic MOTS‑c, restore AMPK signaling, and improve muscle insulin sensitivity without altering plasma MOTS‑c.
Prediction 4: Conversely, muscle‑specific overexpression of MOTS‑c combined with enhanced EV export (via overexpression of Rab27a) will not extend lifespan, whereas overexpression with EV export blocked will produce metabolic benefits.

Experimental Approach

Sample collection: Obtain vastus lateralis biopsies from young (3‑mo) and aged (24‑mo) mice; collect plasma and isolate EVs from muscle interstitial fluid via collagenase digestion followed by ultracentrifugation.
Assays: Quantify total and EV‑associated MOTS‑c by ELISA validated against mass spectrometry; measure phospho‑AMPK, SIRT1, and PGC‑1α by Western blot; assess EV markers (CD63, TSG101) to confirm purity.
Interventions: Treat aged mice with GW4869 (EV release inhibitor) or vehicle for 8 weeks; monitor glucose tolerance, muscle strength, and survival.
Genetic models: Generate HSA‑Cre;MOTS‑c^fl/fl (muscle‑specific KO) and HSA‑Cre;MOTS‑c^OE (overexpression) lines, crossed with Rab27a^fl/fl or Rab27a^OE to modulate EV export.

Falsifiability

If EV‑associated MOTS‑c does not increase with age, or if blocking EV release fails to raise cytosolic MOTS‑c and improve AMPK signaling, the hypothesis would be refuted. Likewise, a strong positive correlation between plasma MOTS‑c and muscle EV‑MOTS‑c would contradict the sequestration model.

Broader Implications

This model re‑positions MOTS‑c from a circulating longevity hormone to a mitochondrially derived stress sensor whose activity is gated by vesicular trafficking. It explains why commercial supplements that raise plasma MOTS‑c show inconsistent benefits and underscores the need to assay tissue‑specific or EV‑linked pools when evaluating MDPs as biomarkers or therapeutic targets.

References: ’s critique of MOTS‑c evidence https://pmc.ncbi.nlm.nih.gov/articles/PMC9570330/, humanin superiority https://gero.usc.edu/2020/06/24/protein-in-mitochondria-may-regulate-health-and-longevity/, compensatory mitochondrial stress https://doi.org/10.1101/2023.10.24.563703, commercial supplement claims https://mimiohealth.com/blogs/news/best-longevity-supplements-2026-science-backed-guide

Hypothesis

Mechanistic Rationale

MOTS‑c synthesis and mitochondrial retention – Under rising mitochondrial ROS with age, MOTS‑c translation increases as part of the mitochondrial stress response (see ’s discussion of compensatory accumulation).

Vesicular loading – Cytosolic MOTS‑c is recognized by the ESCRT‑dependent sorting machinery via a C‑terminal basic motif (predicted by ModeReduction) and packaged into small EVs that are exported to the interstitial space.

Plasma dilution and clearance – EV‑associated MOTS‑c is rapidly taken up by macrophages or degraded in the lymph, resulting in low and variable plasma concentrations that do not correlate with tissue levels.

Signaling consequence – Sequestration reduces free cytosolic MOTS‑c, attenuating its putative activation of AMPK‑SIRT1‑PGC‑1α axis; the cell instead relies on alternative stress pathways (e.g., ATF4‑CHOP) to maintain homeostasis.

Testable Predictions

Prediction 1: In aged mouse skeletal muscle, the proportion of MOTS‑c associated with EVs (isolated by ultracentrifugation or size‑exclusion chromatography) will be significantly higher than in young muscle, while total muscle MOTS‑c rises.

Prediction 2: Plasma MOTS‑c levels will show no correlation with EV‑associated muscle MOTS‑c across individuals, but EV‑associated muscle MOTS‑c will inversely correlate with phospho‑AMPK activity in the same tissue.

Prediction 3: Genetic or pharmacological inhibition of EV release (e.g., GW4869 to block neutral sphingomyelinase) in aged mice will increase cytosolic MOTS‑c, restore AMPK signaling, and improve muscle insulin sensitivity without altering plasma MOTS‑c.

Prediction 4: Conversely, muscle‑specific overexpression of MOTS‑c combined with enhanced EV export (via overexpression of Rab27a) will not extend lifespan, whereas overexpression with EV export blocked will produce metabolic benefits.

Experimental Approach

Sample collection: Obtain vastus lateralis biopsies from young (3‑mo) and aged (24‑mo) mice; collect plasma and isolate EVs from muscle interstitial fluid via collagenase digestion followed by ultracentrifugation.

Assays: Quantify total and EV‑associated MOTS‑c by ELISA validated against mass spectrometry; measure phospho‑AMPK, SIRT1, and PGC‑1α by Western blot; assess EV markers (CD63, TSG101) to confirm purity.

Interventions: Treat aged mice with GW4869 (EV release inhibitor) or vehicle for 8 weeks; monitor glucose tolerance, muscle strength, and survival.

Genetic models: Generate HSA‑Cre;MOTS‑c^fl/fl (muscle‑specific KO) and HSA‑Cre;MOTS‑c^OE (overexpression) lines, crossed with Rab27a^fl/fl or Rab27a^OE to modulate EV export.

Falsifiability

Broader Implications